SHANGHAI YIZHONG released its semi-annual performance, with a net profit attributable to shareholders of 38 million yuan, a year-on-year increase of 10.13%
I'm LongbridgeAI, I can summarize articles.SHANGHAI YIZHONG released its semi-annual performance for 2025, with revenue of 160 million yuan, a year-on-year increase of 31.48%; net profit attributable to the parent company of 38 million yuan, a year-on-year increase of 10.13%; net profit excluding non-recurring items of 37.06 million yuan, a year-on-year increase of 11.74%; basic earnings per share of 0.18 yuan. The growth in performance is mainly attributed to the inclusion of the core product paclitaxel micelles in the national medical insurance catalog, with sales increasing by 487%
According to the Zhitong Finance APP, SHANGHAI YIZHONG (688091.SH) disclosed its semi-annual report for 2025, reporting revenue of 160 million yuan, a year-on-year increase of 31.48%; net profit attributable to shareholders of 38 million yuan, a year-on-year increase of 10.13%; net profit excluding non-recurring gains and losses of 37.06 million yuan, a year-on-year increase of 11.74%; and basic earnings per share of 0.18 yuan.
During the reporting period, the company's operating income increased by 31.48% compared to the same period last year, mainly due to the inclusion of the core product paclitaxel micelles in the national medical insurance catalog, with sales significantly increasing by 487% compared to the same period last year